InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.87
(
0.10%
)
Bitcoin
65,083.38
(
-0.09%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: DewDiligence post# 156483

Tuesday, 02/05/2013 9:00:01 PM

Tuesday, February 05, 2013 9:00:01 PM

Post# of 252254

I’m not as cynical as oc631, so I don’t think GILD is seeking to profit by treating many genotype-3 patients twice rather than once.





You are putting words in my mouth. I didn't say retreatment was part of GILD's overall strategy. This situation is a result of GILD's shortcomings in HCV in-house development and the combo should not be approved for GT3.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up